Pulmonary Circulation is a leading open-access journal published by Wiley, focused on advancing the field of pulmonary and respiratory medicine. Established in 2011, the journal has garnered a prestigious reputation, achieving a Q2 ranking in 2023 among its category and ranking #70 out of 155 in Scopus within the specialty of Medicine – Pulmonary and Respiratory Medicine, reflecting its growing influence and relevance in the scientific community. With its commitment to delivering high-quality, peer-reviewed research, Pulmonary Circulation serves as a vital resource for researchers, clinicians, and students seeking to explore innovative ideas and findings in lung health, pulmonary vascular diseases, and therapeutic approaches. The journal has been open access since 2017, ensuring that groundbreaking research is accessible to a wider audience, thus promoting collaboration and knowledge exchange in this dynamic field. Located in the heart of the United States at 111 River St, Hoboken, NJ 07030-5774, the journal is dedicated to fostering advancements in pulmonary health and addressing real-world challenges facing patients globally.

Lung India is a premier open-access journal dedicated to the dissemination of high-quality research in the field of Pulmonary and Respiratory Medicine. Published by Wolters Kluwer Medknow Publications, it has been forging a path in respiratory healthcare since its inception in 2004. With its impactful contributions to clinical practice and research, Lung India holds a solid position in the academic landscape, evidenced by its ranking in the Q3 quartile for Pulmonary and Respiratory Medicine as of 2023, and its Scopus rank of #99 out of 155. The journal is particularly important for researchers, clinicians, and students in India and beyond, providing a platform for the latest findings and developments in respiratory care, lung disease management, and innovative treatment methods. With a commitment to accessibility, Lung India aims to promote knowledge sharing among professionals and support the advancement of respiratory health. The journal is well-equipped to cater to a diverse audience, ensuring that vital research is readily accessible and impactful.

INFECTION is a prestigious journal, published by Springer Heidelberg, that serves as a leading platform for the dissemination of critical research in the fields of Infectious Diseases, Microbiology, and Medicine. With an impressive Q1 ranking in multiple categories such as Infectious Diseases, Medicine (miscellaneous), and Medical Microbiology, the journal is recognized for its high-quality content and impactful contributions to the scientific community, as evidenced by its Scopus rankings placing it in the top 10th percentiles. Since its inception in 1973, and projected to continue until 2024, INFECTION has established itself as a vital resource for researchers, healthcare professionals, and students keen to explore the latest findings and advancements in infectious diseases. The journal provides a rigorous peer-review process, ensuring that only high-quality studies are published, making it an essential read for those seeking to deepen their understanding and stay abreast of the rapidly evolving landscape in infection research.

Welcome to the Journal of Thoracic Disease, a premier scholarly journal dedicated to advancing the field of pulmonary and respiratory medicine. Published by AME PUBLISHING COMPANY in Hong Kong, this journal has established itself as a critical platform for the dissemination of innovative research and clinical advancements since its inception in 2009. With an impressive Q2 ranking in the Scopus category of Pulmonary and Respiratory Medicine, it is recognized for its contribution to the academic community, featuring a broad range of original research, reviews, and case studies that address contemporary challenges in thoracic disease management. The journal is committed to Open Access principles, ensuring that high-quality research is readily available to a global audience, further enhancing its impact factor and reach. Researchers, healthcare professionals, and students alike will find invaluable insights within its pages, making Journal of Thoracic Disease an essential resource for those invested in the respiratory health domain.

JOURNAL OF CLINICAL INVESTIGATION is a premier scholarly journal published by the American Society for Clinical Investigation, dedicated to advancing the field of clinical research and medicine since its inception in 1945. With an impressive impact factor and ranked Q1 in the field of Medicine (miscellaneous), it stands out as a leading source of high-quality research, reflecting its exceptional position in Scopus ranking as #13 out of 636 in General Medicine, placing it in the 98th percentile. The journal focuses on groundbreaking studies that explore the underlying mechanisms of human disease, facilitating a deeper understanding that drives clinical practice and innovation. Although it is not an open-access journal, the insights and findings published in this esteemed journal are essential reading for researchers, healthcare professionals, and students aspiring to contribute to the dynamic landscape of clinical investigation. Published in the United States, it continues to shape the dialogue and advancement within the medical community through its rigorous peer-review process and commitment to excellence.

THORAX is a premier academic journal dedicated to advancing knowledge in the field of Pulmonary and Respiratory Medicine. Published by the esteemed BMJ Publishing Group in the United Kingdom, this journal has been a pivotal resource for researchers and clinicians since its inception in 1946. With a remarkable ranking of #6 out of 155 in its category, THORAX holds a prestigious position within the top 4% of its field, as indicated by its 2023 Q1 quartile classification and a strong Scopus ranking. The journal focuses on publishing high-quality research, reviews, and clinical studies that are essential for understanding respiratory diseases and their management. Although it is not an open-access journal, THORAX provides vital contributions to the academic community, fostering dialogue and innovation in pulmonary medicine. As it approaches its converged years, concluding in 2024, researchers, professionals, and students are encouraged to explore its rich repository of knowledge, while engaging with the most current advancements in the field.

The Egyptian Journal of Chest Diseases and Tuberculosis is a premier Open Access journal published by Wolters Kluwer Medknow Publications, focusing on the latest advancements in the fields of respiratory diseases, pulmonary medicine, and tuberculosis management. With an ISSN of 0422-7638 and an E-ISSN of 2090-9950, this journal aims to disseminate high-quality research, reviews, and clinical insights that advance the understanding and treatment of chest diseases. Since its transition to Open Access in 2018, the journal has garnered increased visibility, enabling researchers across the globe to contribute and access valuable content without barriers. Situated in India, the journal is dedicated to bridging the gap between clinical practice and research, emphasizing the significance of innovative therapeutic strategies and public health approaches in combating respiratory illnesses. We invite researchers, healthcare professionals, and students to engage with our publications as we continue to foster knowledge and foster collaboration within the global medical community.

Hepatology Research, ISSN 1386-6346 and E-ISSN 1872-034X, is a premier academic journal published by Wiley that serves the dynamic fields of Hepatology and Infectious Diseases. With an impressive 2023 impact factor and ranked Q2 in Hepatology and Q1 in Infectious Diseases, this journal stands out as a vital resource for researchers, professionals, and students. Covering a broad spectrum of topics related to liver health, the journal aims to disseminate cutting-edge research and insights from the converged years of 1997 to 2024. As an open-access platform, it fosters the global sharing of knowledge, providing valuable access to pioneering studies that address pressing issues in liver disease and its associated infections. Based in the United Kingdom, at 111 River St, Hoboken, NJ, Hepatology Research is pivotal for advancing scientific understanding and improving patient outcomes worldwide.

Pulmonology, an esteemed journal published by Elsevier, serves as a vital platform for advancing knowledge in the field of Pulmonary and Respiratory Medicine. Since its transition to Open Access in 2018, this journal has successfully fostered a global readership, allowing for unrestricted dissemination of cutting-edge research. With an impressive Scopus ranking of #8 out of 155 in its category and a notable 2023 Q1 status, Pulmonology consistently showcases high-quality studies and reviews that contribute to the understanding and treatment of respiratory disorders. Authors and readers alike benefit from its commitment to publish influential research that addresses contemporary challenges in lung health. By bridging the gap between theory and clinical practice, the journal paves the way for innovative practices in pulmonology, making it an indispensable resource for researchers, healthcare professionals, and students interested in this dynamic field.

Clinical Lung Cancer is a prestigious journal published by CIG MEDIA GROUP, LP, dedicated to advancing the field of oncology and pulmonary medicine since its establishment in 2000. With an impressive impact factor and high ranking within its fields—achieving Q1 status in Oncology and Pulmonary and Respiratory Medicine in 2023—this journal serves as a vital resource for researchers, clinicians, and students alike. Covering a wide scope of topics related to lung cancer, Clinical Lung Cancer offers a platform for innovative studies, clinical trials, and comprehensive reviews that contribute to both theory and practice. While it operates on a subscription basis, the quality of content is reflected in its ranked status within the top quartile of cancer research journals. This journal plays a critical role in shaping the future of lung cancer research and treatment, making it an essential destination for those looking to stay at the forefront of the field.